Resource Center

Go back to Resource Center

Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial

May/2021

Conference Paper

Authors:
, ; Oden, N.; VanVeldhuisen, P.C.; VanVeldhuisen, P.C.

Secondary:
Association for Research in Vision and Ophthalmology Annual Meeting

Location:
Virtual

URL:
https://www.arvo.org/annual-meeting/https://www2.emmes.com/node/3113

Keywords:
SCORE2

Abstract:
SCORE2 demonstrated that, for visual acuity letter score (VALS) change, bevacizumab is non-inferior to aflibercept for treatment of macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO). While bevacizumab was non-inferior, aflibercept had a numerical advantage in VALS letters gained. The average cost for aflibercept is 10 times that of bevacizumab, but it is not known whether the increased VALS gained offsets this cost.

Go back to Resource Center